Pharmaceutical Business Review
Return to: PBR Home

News

View news from other Pharmaceutical sectors:
16-30 of 50849 results
NICE says lenvatinib should be available on NHS
The National Institute for Health and Care Excellence (NICE) has announced that lenvatinib should be available on the National Health Service (NHS) to give people with advanced kidney cancer a new treatment option.
Drug Research > Drug Delivery > News
Aerogen Pharma, Lyomark Pharma to develop inhaled surfactant
Aerogen Pharma and Lyomark Pharma have partnered to develop a clinically superior treatment for Respiratory Distress Syndrome (RDS), a life-threatening condition of preterm infants associated with long-term lung health issues in survivors.
Drug Research > Drug Discovery & Development > News
Lilly’s Cyramza meets primary endpoint in phase 3 gastric cancer trial
By PBR Staff Writer
Eli Lilly and Company’s (Lilly) phase 3 trial of Cyramza (ramucirumab) for the treatment of a type of gastric cancer was a mixed bag as it met its primary objective of preventing the condition from advancing but could not improve overall survival (OS).
Contract Research & Services > Clinical Trials > News
Roche’s lung cancer drug combo study shows improvement in progression-free survival
By PBR Staff Writer
Roche has announced that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy (carboplatin and paclitaxel) has extended the life of patients with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC) in the Phase III IMpower150 study.
Contract Research & Services > Clinical Trials > News
Report expects global cryotherapy market to cross $4bn by 2024
A new report from Persistence Market Research expects worldwide cryotherapy market to exceed $4bn by 2024.
Drug Research > Drug Delivery > News
bluebird bio, TC BioPharm to develop Gamma Delta CAR T cell product candidates for cancer immunotherapy
bluebird bio and Scottish immunotherapy company TC BioPharm have partnered and signed a license agreement on gamma delta CAR T cells.
Drug Research > Drug Discovery & Development > News
Gilead Sciences to acquire Cell Design Labs in $567m deal
By PBR Staff Writer
Gilead Sciences and its cell therapy subsidiary Kite have agreed to acquire Cell Design Labs, a biotherapeutics company that discovers and develops cell-based therapies, for about $567m.
Drug Research > Drug Discovery & Development > News
GSK to invest £40m in UK's life sciences sector
By PBR Staff Writer
GlaxoSmithKline (GSK) has agreed to invest £40m in genetic research as part of the UK Government’s life sciences sector deal.
Drug Research > Drug Discovery & Development > News
Fate Therapeutics, University of California San Diego launch CAR NK Cancer immunotherapy collaboration
Fate Therapeutics has partnered with the University of California San Diego to develop off-the-shelf, chimeric antigen receptor (CAR)-targeted natural killer (NK) cell cancer immunotherapies.
Drug Research > Drug Discovery & Development > News
Carmot, Amgen form drug discovery partnership
Carmot Therapeutics has entered into a multi-year drug discovery collaboration and licensing agreement with Amgen. The collaboration intends to identify novel molecules aimed for Parkinson’s disease.
Drug Research > Drug Discovery & Development > News
Novartis' Kisqali improves PFS in younger women with advanced breast cancer
By PBR Staff Writer
Results from a phase 3 clinical trial evaluating Novartis' Kisqali (ribociclib) in premenopausal women with HR+/HER2- advanced/metastatic breast cancer demonstrated a significant treatment benefit.
Contract Research & Services > Clinical Trials > News
Janssen’s Imbruvica- rituximab combination meets primary end point in phase 3 study
By PBR Staff Writer
Janssen Research & Development (Janssen) has announced that the combination of Imbruvica (ibrutinib) and rituximab (Rituxan) has improved progression-free survival (PFS) in patients with Waldenstrom macroglobulinemia (WM) in the Phase 3 iNNOVATE (PCYC-1127) study.
Contract Research & Services > Clinical Trials > News
Arena, Everest Medicines partner for Ralinepag and Etrasimod in China
Arena Pharmaceuticals and Everest Medicines have entered into a development and commercialization partnership for ralinepag and etrasimod in mainland China, Taiwan, Hong Kong, Macau, and South Korea (the "Territories").
Production & Manufacturing > Manufacturing > News
Realm Therapeutics doses first patient in phase 2 study of PR022 to treat atopic dermatitis
Realm Therapeutics announced that the first patient has been dosed in its Phase 2 study of PR022, the Company's proprietary topical gel formulation of high concentration hypochlorous acid, for the treatment of atopic dermatitis.
Contract Research & Services > Clinical Trials > News
Novo Nordisk’s Ozempic diabetic drug secures FDA approval
By PBR Staff Writer
Novo Nordisk’s Ozempic (semaglutide injection) has been approved by the US Food and Drug Administration (FDA) to enhance glycaemic control in adults with type 2 diabetes mellitus.
News
16-30 of 50849 results